Table 2 Rates of control for secondary prevention measures by study group
Observation (N = 71) | Control (N = 22) | Intervention (N = 16) | ||||
|---|---|---|---|---|---|---|
Baseline | 12 months | Baseline | 12 months | Baseline | 12 months | |
Antiplatelet use | 50/71 (70.4%) | 51/71 (71.8%) | 17/22 (77.3%) | 15/22 (68.2%) | 10/16 (62.5%) | 10/16 (62.5%) |
Systolic BP (mmHg) | 147.8 (21.2) | 152.1 (18.1) | 148.3 (20.3) | 152.4 (23.3) | 143.7 (14.2) | 156.1 (19.4) |
Diastolic BP (mmHg) | 80.3 (10.4) | 84.5 (10.9) | 80.2 (10.8) | 81.1 (14.3) | 82.7 (10.0) | 88.9 (12.5) |
BP < 130/80 mmHg | 7/71 (9.9%) | 2/71 (2.8%) | 2/22 (9.1%) | 1/22 (4.5%) | 2/16 (12.5%) | 0/16 (0.0%) |
BP < 140/90 mmHg | 24/71 (33.8%) | 19/71 (26.8%) | 7/22 (31.8%) | 5/22 (22.7%) | 6/16 (37.5%) | 2/16 (12.5%) |
Total Cholesterol (mmol/L) | 4.9 (1.1) | 4.4 (1.0) | 4.9 (1.0) | 4.3 (1.0) | 4.1 (0.8) | 3.9 (1.0) |
Total Cholesterol < 4.0 mmol/L | 16/71 (22.5%) | 28/71 (39.4%) | 4/22 (18.2%) | 10/22 (45.5%) | 8/16 (50.0%) | 10/16 (62.5%) |
Heart rate (beats per min)a, | 75.7 (12.1) | 74.5 (12.3) | 68.4 (13.8) | 72.3 (18.9) | 78.3 (5.5) | 71.1 (10.5) |
HR 60-80 bpma | 10/21 (47.6%) | 12/23 (52.2%) | 2/3 (66.7%) | 2/6 (33.3%) | 3/5 (60.0%) | 5/7 (71.4%) |
Adequate anticoagulationa,b | 8/21 (38.1%) | 18/23 (78.3%) | 3/3 (100.0%) | 5/6 (83.3%) | 1/5 (20.0%) | 6/7 (85.7%) |
HbA1C mmol/molc | 51.0 (44.3, 64.3) | 49.0 (44.0, 69.3) | 80.0 (−) | 66.0 (−) | 53.5 (−) | 62.0 (−) |
HbA1C 48-53 mmol/molc | 5/15 (33.3%) | 4/17 (23.5%) | 0/3 (0.0%) | 0/3 (0.0%) | 1/2 (50.0%) | 1/3 (33.3%) |